



Please type a plus sign (+) inside this box →

1647

Approved for use through 09/30/2000, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

RECEIVED

Total Number of Pages in This Submission

14

Application Number

09/898,751

Filing Date

July 2, 2001

First Named Inventor

Wei Wang

Group Art Unit

1647

MAR 06 2003

Examiner Name

Bunner, Bridget

TECH CENTER 1600/2900

Attorney Docket Number

DX0882XK

ENCLOSURES (check all that apply)

- Fee Transmittal Form
- Fee Attached
- Amendment / Response
 - After Final
 - Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority Document(s)
- Response to Missing Parts/ Incomplete Application
- Response to Missing Parts under 37 CFR 1.52 or 1.53

- Assignment Papers (for an Application)
- Drawing(s)
- Licensing-related Papers
- Petition Routing Slip (PTO/SB/69) and Accompanying Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation Change of Correspondence Address
- Terminal Disclaimer
- Small Entity Statement
- Request for Refund

- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Additional Enclosure(s) (please identify below)

7 References w/Response
Certificate of Mailing 1 pg.
Return Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual name

Sandy Zaradic, Reg. No. 45,997

Signature

Date

February 28, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name

Signature

Date

+ Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Attorney Docket No.: DX0882XK

Serial No.: 09/898,751

Filing Date: July 2, 2001

Inventor: Wei Wang

PTO/SB92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

**Assistant Commissioner for Patents
Washington, D.C. 20231**


RECEIVED

on February 28, 2003.

MAR 06 2003

Date

TECH CENTER 1600/2900


Signature

SANDY ZARADIC, Reg. No. 45,997

Typed or printed name of person of signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Documents enclosed:

Transmittal Sheet - 1 page

Response to Office Action - 12 pages

References in support of Response - 7

Certificate of Mailing- 1 page

Return Postcard

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PATENT CASE: DX0882XK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Wei Wang *et al.* : Examiner: Bunner, Bridget E.
For: Chemokine and Receptor Uses; :
Compositions; Methods : Group Art Unit: 1647
Serial No.: 09/898,751 :
Filing Date: July 2, 2001 :
x February 28, 2003

#13B/PW
031803

RECEIVED

MAR 06 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION

This is in response to the Office Action, Paper No. 12, (Confirmation No. 7429) mailed November 29, 2002, for which a response is due February 28, 2003.

PLEASE AMEND THE APPLICATION AS FOLLOWS:

IN THE SPECIFICATION

Prior to the first sentence of the specification, please include the following:

B1 This is a continuation-in-part of U.S. Application No. 09/471,549, filed December 23, 1999, now abandoned.

At the top of pages 1 and 102, please replace the present title with the following title:

METHOD OF IMPAIRING MOVEMENT OF A CLA⁺ MEMORY T-CELL WITHIN OR
TO THE SKIN OF A MAMMAL BY ADMINISTERING A CTACK ANTAGONIST.

On page 9, lines 3-20, please replace the present pending text with the following:

B2 The described chemokines or receptors should be important for mediating various aspects of cellular, organ, tissue, or organismal physiology or development. In particular, the Vic chemokine is a classic pro-inflammatory chemokine, which mediates inflammatory processes. The CTACK is a cutaneously expressed chemokine. See, e.g., USSN 08/978,964 (now abandoned) and related cases.

In contrast to naive lymphocytes, memory/effector lymphocytes can access non-lymphoid effector sites and display restricted, often tissue-selective, migration behavior. The cutaneous lymphocyte-associated antigen (CLA) defines a well described subset of circulating memory T cells that selectively localize in cutaneous sites mediated in part by the interaction of CLA with its vascular ligand E-selectin. Picker, et al. (1991) Nature 349:796-799; and Rossiter, et al. (1994) Eur. J. Immunol. 24:205-210. E-selectin is broadly expressed in inflamed endothelium; thus, specific infiltration of skin by CLA⁺ cells must require additional cues. Herein is description of particular C-C chemokines, one originally designated GWCC but herein referred to as